Read on Twitter
Meta-analysis of antibiotic prescribing in #COVID19 inpatients finds:
-74.6% received antibiotics
-8.6% had bacterial co-infection
At first glance, this suggests that we’re *way* overprescribing Abx in COVID. But there are some caveats.
1/3 https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30778-3/fulltext#.X_RLIWKUpzc.twitter
-74.6% received antibiotics
-8.6% had bacterial co-infection
At first glance, this suggests that we’re *way* overprescribing Abx in COVID. But there are some caveats.
1/3 https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30778-3/fulltext#.X_RLIWKUpzc.twitter
First, Abx prescribing was much higher earlier in the pandemic (January 86% vs April 63%) and higher in China (76%) compared to the US (65%) & Europe (63%).
This suggests that overprescribing may be less of an issue currently and in the US.
2/3
This suggests that overprescribing may be less of an issue currently and in the US.
2/3
Second, only 5 studies (out of 154) reported the Abx duration. We don’t know if Abx was quickly de-escalated (appropriate) vs continued despite (-)cultures (inappropriate).
IMO It’s not wrong to start Abx in sick COVID pts so long as you promptly d/c when cultures are (-)
3/4
IMO It’s not wrong to start Abx in sick COVID pts so long as you promptly d/c when cultures are (-)
3/4
Finally, we don’t know what triggered Abx use. Protocolized Abx is probably wrong. But using high PCT, high WBC count, or imaging findings to trigger Abx seems reasonable.
Conclusion: we probably do overuse Abx in COVID but it’s hard to identify the pts who really need em.
4/4
Conclusion: we probably do overuse Abx in COVID but it’s hard to identify the pts who really need em.
4/4
